Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
CONCLUSION: PD-1/PD-L1 inhibitors are generally safer and better tolerated than chemotherapy for patients with NSCLC with regard to summary toxic events, detailed toxic symptoms and hematologic toxicities. However, PD-1/PD-L1 inhibitors can generate a unique spectrum of irAEs, and several of them can be severe and even life-threatening. Clinicians should be aware of the risk of these AEs, as they may have a potentially negative impact on the patients' quality of life and survival outcome.
PMID: 30019319 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Luo W, Wang Z, Tian P, Li W Tags: J Cancer Res Clin Oncol Source Type: research
More News: Anemia | Anorexia | Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Conferences | Constipation | Databases & Libraries | Eating Disorders & Weight Management | Hematology | Hyperthyroidism | Hypothyroidism | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Study | Thrombocytopenia | Toxicology